{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:31Z","timestamp":1787022091471,"version":"build-2736575974"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac light chain amyloidosis (AL-CA) patients often die within three months of starting chemotherapy. Chemotherapy for non-immunoglobulin M gammopathy with AL-CA frequently includes bortezomib (Bor), cyclophosphamide (Cy), and dexamethasone (D). We previously reported that NT-ProBNP levels can double within 24h of dexamethasone administration, suggesting a deleterious impact on cardiac function. In this study, we evaluate the role of dexamethasone in early cardiovascular mortality during treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We retrospectively assessed 100\n                      <jats:italic>de novo<\/jats:italic>\n                      cardiac AL patients (62% male, mean age 68 years) treated at our institute between 2009 and 2018 following three chemotherapy regimens: CyBorDComb (all initiated on day 1; 34 patients), DCyBorSeq (D, day 1; Cy, day 8; Bor, day 15; 17 patients), and CyBorDSeq (Cy, day 1; Bor, day 8; D, day 15; 49 patients). The primary endpoint was cardiovascular mortality and cardiac transplantation at days 22 and 455. At day 22, mortality was 20.6% with CyBorDComb, 23.5% with DCyBorSeq, and 0% with CyBorDSeq (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003). At day 455, mortality was not significantly different between regimens (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.195). Acute toxicity of dexamethasone was evaluated on myocardial function using a rat model of isolated perfused heart. Administration of dexamethasone induced a decrease in left ventricular myocardium contractility and relaxation (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.05), supporting a potential negative inotropic effect of dexamethasone in AL-CA patients with severe cardiac involvement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Delaying dexamethasone during the first chemotherapy cycle reduces the number of early deaths without extending survival. It is clear that dexamethasone is beneficial in the long-term treatment of patients with AL-CA. However, the initial introduction of dexamethasone during treatment is critical, but may be associated with early cardiac deaths in severe CA. Thus, it is important to consider the dosage and timing of dexamethasone introduction on a patient-severity basis. The impact of dexamethasone in the treatment of AL-CA needs further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0257189","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:51:49Z","timestamp":1631713909000},"page":"e0257189","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-4099","authenticated-orcid":true,"given":"M\u00e9lanie","family":"B\u00e9zard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-5598","authenticated-orcid":true,"given":"Silvia","family":"Oghina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-1880","authenticated-orcid":true,"given":"Damien","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Kordeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnault","family":"Galat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Zaroui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soulef","family":"Guendouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-1947","authenticated-orcid":true,"given":"Floriane","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Shourick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Teiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Poullot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-7295","authenticated-orcid":true,"given":"Val\u00e9rie","family":"Molinier-Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onnik","family":"Agbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Le Bras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":true,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"issue":"12","key":"pone.0257189.ref001","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.,\u201d","volume":"68","author":"R. H. Falk","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"pone.0257189.ref002","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1161\/CIRCULATIONAHA.111.069195","article-title":"Cardiac amyloidosis.","volume":"126","author":"C. C. Quarta","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"pone.0257189.ref003","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13156","article-title":"Guidelines on the diagnosis and investigation of AL amyloidosis.","volume":"168","author":"J. D. Gillmore","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"3","key":"pone.0257189.ref004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.","volume":"133","author":"B. Lilleness","year":"2019","journal-title":"Blood"},{"issue":"11","key":"pone.0257189.ref005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11886-015-0653-1","article-title":"Emerging Advances in the Management of Cardiac Amyloidosis.","volume":"17","author":"M. N. Vranian","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"issue":"18","key":"pone.0257189.ref006","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.","volume":"22","author":"A. Dispenzieri","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"pone.0257189.ref007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"30","author":"S. Kumar","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"17","key":"pone.0257189.ref008","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.","volume":"121","author":"A. D. Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"5","key":"pone.0257189.ref009","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.","volume":"126","author":"G. Palladini","year":"2015","journal-title":"Blood"},{"issue":"9","key":"pone.0257189.ref010","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"\u201cEfficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-na\u00efve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"A. Jaccard","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"pone.0257189.ref011","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.,\u201d","volume":"28","author":"C. P. Venner","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"pone.0257189.ref012","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0002-9149(97)00653-X","article-title":"Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis.","volume":"80","author":"B. Chamarthi","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"pone.0257189.ref013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.02.004","article-title":"Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.","volume":"76","author":"F. Le Bras","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"pone.0257189.ref014","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.","volume":"20","author":"J. Hillengass","year":"2019","journal-title":"Lancet. Oncol."},{"issue":"25","key":"pone.0257189.ref015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.","volume":"134","author":"R. Manwani","year":"2019","journal-title":"Blood"},{"issue":"18","key":"pone.0257189.ref016","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.","volume":"36","author":"R. H. Sayed","year":"2015","journal-title":"Eur. Heart J."},{"issue":"9","key":"pone.0257189.ref017","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/CIRCULATIONAHA.110.010447","article-title":"Cardiac amyloidosis: a treatable disease, often overlooked.","volume":"124","author":"R. H. Falk","year":"2011","journal-title":"Circulation"},{"issue":"1\u20132","key":"pone.0257189.ref018","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11010-016-2846-3","article-title":"Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation.","volume":"424","author":"F. de Salvi Guimar\u00e3es","year":"2017","journal-title":"Mol. Cell. Biochem."},{"issue":"3","key":"pone.0257189.ref019","doi-asserted-by":"crossref","first-page":"E654","DOI":"10.1152\/ajpendo.00453.2006","article-title":"Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism.","volume":"292","author":"D. Qi","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab"},{"issue":"4","key":"pone.0257189.ref020","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1046\/j.1365-2141.2001.02859.x","article-title":"\u201cA modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis","volume":"113","author":"G. Palladini","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"3","key":"pone.0257189.ref021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.","volume":"138","author":"M. Kropff","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"4","key":"pone.0257189.ref022","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bjh.14920","article-title":"Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.","volume":"179","author":"H. Einsele","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"6","key":"pone.0257189.ref023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1006\/phrs.1999.0653","article-title":"The isolated blood and perfusion fluid perfused heart.","volume":"41","author":"F. J. Sutherland","year":"2000","journal-title":"Pharmacol. Res."},{"issue":"7","key":"pone.0257189.ref024","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.","volume":"130","author":"G. P. Kaufman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"pone.0257189.ref025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.","volume":"33","author":"J. P. Abeykoon","year":"2019","journal-title":"Leukemia"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:52:10Z","timestamp":1631713930000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257189"}},"subtitle":[],"editor":[{"given":"Corstiaan","family":"den Uil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0257189","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]}}}